AstraZeneca’s COVID-19 vaccine is found to be 79% effective in U.S. study
By Rebecca Robbins and Benjamin Mueller
The coronavirus vaccine developed by AstraZeneca and the University of Oxford provided strong protection against COVID-19 in a large U.S. clinical trial, completely preventing the worst outcomes from the disease while causing no serious side effects, according to results announced Monday.
The findings, announced in a news release from AstraZeneca, may help shore up global confidence in the vaccine, which was shaken this month when more than a dozen countries, mostly in Europe, temporarily suspended the shot’s use over concerns about possible rare side effects.
The trial, involving more than 32,000 participants, was the largest test of its kind for the shot. The vaccine was 79% effective overall in preventing symptomatic infections, higher than observed in previous clinical trials. The trial also showed that the vaccine offered strong protection for older people, who had not been as well-represented in earlier studies.
But the fresh data may not make much difference in the United States, where the vaccine is not yet authorized.
If AstraZeneca’s vaccine is authorized for U.S. use, it is unlikely to become available before May, when federal officials predict that there will be enough vaccine doses for all the nation’s adults from the three manufacturers that already have authorization.
Even so, industry analysts said the results were better than expected, a heartening turn for a shot whose low cost and simple storage requirements have made it the workhorse of the drive to vaccinate the world.
The results also helped a campaign by European lawmakers to buttress people’s confidence in the shot, one that has featured many political leaders themselves being injected in recent days.
“The results from the U.S. trial of the Oxford-AstraZeneca vaccine give strong evidence that the vaccine is both safe and highly effective,” Matt Hancock, the British health secretary, said Monday. “Vaccines are our way out of this, so when you get the call, get the jab.”
AstraZeneca said Monday that it would continue to analyze the new data and prepare to apply “in the coming weeks” for emergency authorization from the Food and Drug Administration. The vaccine has already been approved in more than 70 countries, but clearance from U.S. regulators would bolster the vaccine’s reputation globally.
The new data have been highly anticipated because of the expectation that the trial, designed to meet FDA standards, would be the best measure of how well the vaccine works. The shot is the backbone of vaccine rollouts in many poor and middle-income countries.
“This is the vaccine that will likely vaccinate the world,” Ashish Jha, the dean of the Brown University School of Public Health, wrote on Twitter on Monday, adding: “If you were rooting for global vaccination, this is a good morning.”
The interim results announced Monday were based on 141 COVID-19 cases that had turned up in volunteers. Two-thirds of participants were given the vaccine, with doses spaced four weeks apart, and the rest received a saline placebo. Volunteers were recruited from Chile and Peru in addition to the United States.
None of the volunteers who got the vaccine developed severe symptoms or had to be hospitalized, a major selling point for the shot. Five participants who were given the placebo developed severe COVID-19, Ruud Dobber, an executive vice president at AstraZeneca, told CNBC on Monday.
The new results could help the vaccine recover from the safety scare it has faced in Europe. Regulators there initiated a safety review after a small number of people who had recently been inoculated developed blood clots and abnormal bleeding.
Most countries are now restarting use of the shot, with some restrictions and a new warning label, after the European Union’s drug regulator said Thursday that a review determined that the vaccine was safe.
Nonetheless, the speed at which several nations suspended use of the vaccine reflected a skittishness about its safety and effectiveness that contrasts sharply with the confidence that has been shown in other vaccines. Trust in the vaccine has tumbled in Germany, France, Italy, Spain and, to a lesser degree, Britain, according to polls.
Participants who received the vaccine in the trial had no increased risk of blood clots or related illnesses. And a specific search turned up no cases of cerebral venous sinus thrombosis — blood clots in the brain that can result in dangerous bleeding — that raised some of the most serious concerns in Europe.
The U.S. trial also turned up no cases of serious neurological problems. That arose as a concern last summer after two volunteers in AstraZeneca’s trial in Britain fell ill with neurological problems. Although those cases forced a seven-week halt to the U.S. clinical study, researchers ultimately concluded that the illnesses could not be linked to the vaccine.
Still, the delay was a key factor in why AstraZeneca fell so far behind three other vaccine manufacturers that have won emergency authorization in the United States.
The vaccine worked well across ethnicity and age groups, AstraZeneca said. The vaccine was 80% efficacious in approximately 6,000 trial enrollees older than 65 — findings likely to quell concerns about insufficient clinical trial data on how well the vaccine works in older people.
Some countries briefly limited inoculations with the shot to younger people before reversing course to allow it to be used in all age groups, after data from the vaccine’s rollout in Britain showed the vaccine provided strong protection in older people.